N/A N=30 Early Interventional Treatment for Cancer Pain
Cancer Pain
Primary: Feasibility - Pain Consultation — 29 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=150 The Effectiveness of Cancer Pain Management in Siriraj Outpatient Pain Clinic
Pain, Chronic · Cancer
Primary: Improvement of Pain. — 3 score on a scale (0-10)
N/A N=262 Computerized PAINRelieveIt Protocol for Cancer Pain Control in Hospice
Cancer · Pain
Primary: Analgesic Adherence-patient — 0.66; 0.67 proportion (0-1), higher is better — p=.43
N/A N=462 Analgesic Treatment for Cancer Pain in South East Asia
Pain
Primary: Prescription Pattern of Analgesics (Opioid or Non-opioid) — 37.27; 11.33; 51.40 percentage of patients
N/A N=185 Improving Cancer Pain Management Through Self-Care
Cancer · Pain
Primary: Average Pain Intensity Score — 1.192; 1.304 units on a scale
N/A N=50 Acceptance and Commitment Therapy for Chronic Pain in Cancer Survivors
Chronic Pain
Primary: The Degree of Effectiveness of Acceptance and Commitment Therapy: [Impact] — 23.9; 21.4; 41.7; 37.5 units on a scale — p=0.82
N/A N=109 Self-Management Interventions for Chronic Pain Relief With Cancer Survivors
Chronic Pain
Primary: Change in Pain Intensity — -1.61; -1.35 score on a scale — p=0.809
Phase 2 N=78 Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
Pain · Cancer
Primary: Percentage of Participants With Sustained Pain Control for 5 Day Fixed Dose Phase — 89.7; 92.9 percentage of participants
Phase 3 N=399 Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
Pain · Advanced Cancer
Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 7.2; 9.5 percent improvement — p=0.2735
Phase 3 N=397 Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
Pain · Advanced Cancer
Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 10.7; 4.5 percent improvement — p=0.0854
N/A N=10 STAMP+CBT mHealth for Cancer Pain
Active Cancer · Active Cancer Treatment · Advanced Cancer
Primary: Overall Intervention Adherence Rate — 15.75 EMA App Surveys
Phase 1 N=66 Marijuana in Combination With Opioids in Palliative and Hospice Patients
Pain
Primary: Primary Reduction of Pain — 2.55; 1.40 units on a scale from 0 to 10
N/A N=46 Intelligent Pain Management System for Assessing Pain in Cancer Patients
Pain · Neoplasms
Primary: Feasibility of Mobile Application Assessed by Observing the Number of Daily Pain Assessments Recorded Among Patients — 2.37 pain assessments per day
Phase 3 N=242 Immediate-Release Oxycodone Capsules Study in Cancer Pain
Cancer
Primary: Numerical Rating Scale (NRS) — 3.91; 3.87 scores on a scale
Phase 3 N=98 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
Brain and Central Nervous System Tumors · Chronic Myeloproliferative Disorders · Leukemia
Primary: Pain Intensity — 5.60; 6.44; 5.11; 5.98 units on a scale
Phase 3 N=406 A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Pain · Advanced Cancer
Primary: Change From Randomization Baseline In Mean NRS Average Pain At End Of Treatment — 0.5; 0.5 units on a scale — p=0.9173
Phase 3 N=177 A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy
Palliative Care · Pain · Cancer
Primary: The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment. — -1.32; -0.93; -0.73 units on a scale — p=0.014
Phase 4 N=518 RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
Cancer · Cancer Pain
Primary: Proportion of Non-Responder (NR) Participants — 14; 18; 14; 11 participants
Phase 2 N=7 Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients
Breast Cancer · Chronic Pain Due to Malignancy (Finding)
Primary: Overall Pain Relief. — 1.9; 0.5 score on a scale
Phase 2 N=78 Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer
Metastatic Cancer · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Participants With Maximum Pain Level Decreased by ≥ 2 Points at 2 Months After Radiofrequency Ablation (RFA) — 83.6 percentage of participants
Phase 2 N=60 MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)
Malignant Neoplasm · Oral Pain · Stomatitis
Primary: Change in Pain Scores Assessed Within the Numeric Rating Scale (NRS) Component of the Modified Harris Mucositis-related Pain Assessment Tool — 1.69; 5.2; 4.54; 5.15…
Phase 3 N=32 Subcutaneous Lidocaine For Cancer-Related Pain
Cancer-related Pain
Primary: Number of Participants With Reduction in Worst Pain Intensity or Reduction in 24hr Opioid Dose of at Least 30% Without Worsening of Pain Scores — 1; 2; 2; 1 Participants
Phase 2 N=79 Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain
Pain
Primary: Change in Patient-reported Worst Pain Between Baseline and 5 Weeks of Treatment With Duloxetine — 6.54; 0.25; 4.06 score on a scale
Phase 3 N=140 Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery
Breast Cancer Patient
Primary: Change in Neuropathic Pain Score at 2 Months (Numeric Rating Scale 0-10) — 4.1; 4.6 units on a scale
N/A N=59 Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study
Chronic Leukemia · Hematopoietic and Lymphoid System Neoplasm · Lymphoma
Primary: Feasibility of Intervention — 41; 17; 11; 5 Participants
N/A N=3,765 Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
Breakthrough Cancer Pain
Primary: Percentage of Cancer Participants With Breakthrough Cancer Pain From the Total Number of Cancer Participants Seen in Consultation — 14.3 percentage of participants
Phase 3 N=156 Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Bone Metastasis · Cancer Pain
Primary: Change From Baseline in the Daily Average Pain Intensity Numerical Rating Score (NRS) in the Index Bone Metastasis Cancer Pain Site at Week 8 — -1.25; NA; NA; -2.03…
Phase 3 N=340 A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain
Pain
Primary: Change From Baseline to the Last 3 Days of Study Drug Administration (Last Observation Carried Forward) in the Score for Average Pain Intensity on an 11-point Numerical…
N/A N=20 Smartphone Technology to Alleviate Malignant Pain (STAMP)
Cancer · Pain Management · Opioid Use
Primary: Frequency of Patient Log Ins — 14 log ins to the application per patient
Phase 2 N=27 Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease
Sickle Cell Disease
Primary: Pain Rating Using Visual Analog Scale at Day 1 and Day 5 — 40.5; 45.8; 30.3; 38.5 score on a scale